ESLA
Estrella Immunopharma Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$71.68M
P/E Ratio
—
EPS
$-0.35
Beta
0.58
52W High
$3.15
52W Low
$0.78
50-Day MA
$1.33
200-Day MA
$1.38
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -268.50% |
| Return on Assets | -258.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.27 |
| Price-to-Book | 4.13 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.67M |
| Float | $18.02M |
| % Insiders | 61.13% |
| % Institutions | 2.46% |
Historical Volatility
HV 10-Day
95.09%
HV 20-Day
146.04%
HV 30-Day
127.69%
HV 60-Day
113.89%
HV Rank
80.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($12.00 target)
1
BuyData last updated: 4/28/2026